FDA approves generic Casodex from Sun, Mylan

07/7/2009 | Forbes

Mylan and Sun Pharmaceutical Industries secured FDA clearance for their generic copies of AstraZeneca's prostate cancer drug Casodex. Total U.S. sales of Casodex reached $322 million for the year that ended March 31, said Mylan, which has begun shipping its bicalutamide tablets.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD